Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

NCT04848454 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

HER2-negative Breast Cancer
Neoadjuvant Therapy
Pathological Complete Response
Immunotherapy
Vinorelbine
Cisplatin

Interventions

DRUG: Camrelizumab with vinorelbine and cisplatin

Sponsor

Peking University First Hospital